Management of High Disease Activity in Multiple Sclerosis Using Zytux TM (Rituximab, AryoGen Pharmed): Evidence from a Case Report

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

NASER MOGHADASI ABDORREZA; Ghoreyshi Tayyebi Esmaeil

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Journal of Kermanshah University of Medical Sciences Year:2020 | Volume:24 | Issue:1 Page(s): 0-0

Download Full-Text

View:

Download:

Cites:

Information Journal Paper

Title

Management of High Disease Activity in Multiple Sclerosis Using Zytux TM (Rituximab, AryoGen Pharmed): Evidence from a Case Report

Author(s)

NASER MOGHADASI ABDORREZA | Ghoreyshi Tayyebi Esmaeil | Issue Writer Certificate

Keywords

Zytux TM

Rituximab

Highly Active Multiple Sclerosis

MRI

Abstract

Rituximab is an anti-CD20 monoclonal antibody, which is used for the treatment of various autoimmune diseases. Owing to its marked effect on B cells, Rituximab has also been used in the treatment of fulminant multiple sclerosis. The present study aimed to describe the case of a patient with fulminant radiological presentation, which was effectively controlled using Rituximab. A 21-yearold woman initially presented with vertigo, which resolved spontaneously. The MRI indicated extensive periventricular involvement with multiple enhancing lesions. The patient was hospitalized and received pulse methylprednisolone (1 g) daily for five days. Afterwards, she was administered with Zytux TM (1 g; Rituximab, AryoGen Pharmed) for two weeks.

Cites

No record.

References

No record.

Cite

APA: Copy

NASER MOGHADASI, ABDORREZA, & Ghoreyshi Tayyebi, Esmaeil. (2020). Management of High Disease Activity in Multiple Sclerosis Using Zytux TM (Rituximab, AryoGen Pharmed): Evidence from a Case Report. JOURNAL OF KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES (BEHBOOD), 24(1), 0-0. SID. https://sid.ir/paper/696538/en

Vancouver: Copy

NASER MOGHADASI ABDORREZA, Ghoreyshi Tayyebi Esmaeil. Management of High Disease Activity in Multiple Sclerosis Using Zytux TM (Rituximab, AryoGen Pharmed): Evidence from a Case Report. JOURNAL OF KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES (BEHBOOD)[Internet]. 2020;24(1):0-0. Available from: https://sid.ir/paper/696538/en

IEEE: Copy

ABDORREZA NASER MOGHADASI, and Esmaeil Ghoreyshi Tayyebi, “Management of High Disease Activity in Multiple Sclerosis Using Zytux TM (Rituximab, AryoGen Pharmed): Evidence from a Case Report,” JOURNAL OF KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES (BEHBOOD), vol. 24, no. 1, pp. 0–0, 2020, [Online]. Available: https://sid.ir/paper/696538/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops